Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BioDrugs ◽  
2018 ◽  
Vol 32 (5) ◽  
pp. 415-423 ◽  
Author(s):  
Feng Huang ◽  
Zu-chun Luo
Sign in / Sign up

Export Citation Format

Share Document